The Effect of Vitamin K2 in Addition to Risedronate on the Patients with Postmenopausal Osteoporosis
Journal of the Korean Academy of Rehabilitation Medicine
;
: 491-495, 2006.
Artigo
em Coreano
| WPRIM
| ID: wpr-722530
ABSTRACT
OBJECTIVE:
To assess the effect of vitamin K2 in addition to risedronate on postmenopausal osteoporosisMETHOD:
We enrolled 21 postmenopausal osteoporosis women (age 65.2+/-7.8 years). Ten subjects received risedronate (35 mg, weekly) and vitamin K2 (45 mg, daily) and eleven subjects only received risedronate. They all received calcium citrate 2,130 mg and vitamin D 600 IU daily. The duration of treatment was 7.7+/-1.4 months. Bone mineral density (BMD) of lumbar spine and both femurs, serum osteocalcin and urine deoxypyridinoline were examined at baseline and after treatment.RESULTS:
After treatment, BMD, serum osteocalcin and urine deoxypyridinoline were improved in each group but there was no statistical difference between the groups.CONCLUSION:
There was no evidence of the benefit of vitamin K2 in addition to risedronate in bone metabolism on postmenopausal osteoporosis.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Coluna Vertebral
/
Vitamina D
/
Vitaminas
/
Densidade Óssea
/
Osteocalcina
/
Osteoporose Pós-Menopausa
/
Citrato de Cálcio
/
Vitamina K 2
/
Fêmur
/
Ácido Risedrônico
Limite:
Feminino
/
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Academy of Rehabilitation Medicine
Ano de publicação:
2006
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS